DualityBio tries to float again
The group expects to raise nearly $170m.
Enhertu could fill a gastric hole
The first-line Destiny-Gastric05 trial includes a PD-L1-negative cohort.
Boehringer beats Bayer to the regulators
The FDA will rule on a low dose of zongertinib in the summer.
